Inovio Pharmaceuticals
INO
213 hedge funds and large institutions have $555M invested in Inovio Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 58 increasing their positions, 60 reducing their positions, and 26 closing their positions.
27% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 26
1% more funds holding
Funds holding: 211 → 213 (+2)
0.12% more ownership
Funds ownership: 2.95% → 3.07% (+0.12%)
3% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 60
19% less capital invested
Capital invested by funds: $682M → $555M (-$127M)
21% less call options, than puts
Call options by funds: $25.6M | Put options by funds: $32.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$17.1M |
| 2 |
D.E. Shaw & Co
New York
|
+$14.2M |
| 3 |
JP Morgan Chase
New York
|
+$5.61M |
| 4 |
Goldman Sachs
New York
|
+$3.81M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$10.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.14M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.51M |
| 4 |
Citigroup
New York
|
-$2.07M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.75M |
INO Hedge Fund Activity: Q3 2021 in Review
213 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2021, worth a combined $555M — down 19% from $682M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new INO positions and 26 closed out — a net gain of 7 holders — while 58 added to existing stakes and 60 trimmed.
The largest buyer was State Street, adding an estimated $17.1M. The largest seller was Nuveen, cutting an estimated $10.2M.
- 213 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2021, up from 211 in Q2 2021.
- Funds reported $555M of Inovio Pharmaceuticals stock for Q3 2021, down 19% quarter-over-quarter.
- 33 funds opened new Inovio Pharmaceuticals positions in Q3 2021 and 26 closed out, a net change of +7 holders.
- The largest Inovio Pharmaceuticals buyer in Q3 2021 was State Street, an estimated $17.1M added.
- The largest Inovio Pharmaceuticals seller in Q3 2021 was Nuveen, an estimated $10.2M sold.
Based on aggregated 13F filings for Q3 2021.